Harbour BioMed’s US$220 Million Hong Kong IPO And Listing

Clifford Chance has advised the joint sponsors Morgan Stanley, Bank of America Securities, CLSA and joint global coordinators CICC and Credit Suisse on biopharmaceutical company Harbour…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Michael Patrini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here